Endoscopic resection combined with the Cryoballoon focal ablation system in the porcine normal esophagus: a preclinical study

Abstract Background The Cryoballoon focal ablation system (CbFAS) for dysplastic Barrett’s esophagus is simple, time-saving and has high therapeutic efficacy. This study aimed to evaluate the technical feasibility and tissue damage with combination therapy of endoscopic resection (ER) and CbFAS in porcine models. Methods Three pigs (A, B, and C) were included, and all ER procedures were performed by endoscopic mucosal resection using the Cap method (EMR). Combination therapy for each pig was performed as follows: (a) CbFAS was performed for a post-EMR mucosal defect for Pig A; (b) CbFAS for post-EMR scar for Pig B, and (c) EMR for post-CbFAS scar for Pig C. All pigs were euthanized at 32 days after the initial procedure, and the tissue damage was evaluated. Results All endoscopic procedures were followed as scheduled. None of the subjects experienced anorexia, rapid weight loss, bleeding, and perforation during the observation period. They were euthanized at 32 days after the initial endoscopic procedure. On histological assessment, there was little difference between the tissue that was treated with CbFAS alone and that treated with CbFAS in combination with ER. Conclusion Combination therapy with ER and CbFAS can be technically feasible, and its outcome was not significantly different from CbFAS alone in terms of tissue damage.

Download Full-text

Endoscopic Resection Combined with the Cryoballoon Focal Ablation system in the Porcine Normal Esophagus: A Preclinical Study

10.21203/rs.3.rs-196161/v1 ◽

2021 ◽

Author(s):

Hironori Sunakawa ◽

Yusuke Yoda ◽

Nobuyoshi Takeshita ◽

Hiro Hasegawa ◽

Kenji Takashima ◽

...

Keyword(s):

Combination Therapy ◽

Endoscopic Resection ◽

Tissue Damage ◽

Preclinical Study ◽

Rapid Weight Loss ◽

Time Saving ◽

Mucosal Defect ◽

Normal Esophagus ◽

Initial Procedure ◽

Focal Ablation

Abstract Background: The Cryoballoon focal ablation system (CbFAS) for dysplastic Barrett’s esophagus is simple, time-saving and has high therapeutic efficacy. This study aimed to evaluate the technical feasibility and tissue damage with combination therapy of endoscopic resection (ER) and CbFAS in porcine models.Methods: Three pigs (A, B, and C) were included, and all ER procedures were performed by endoscopic mucosal resection using the Cap method (EMR). Combination therapy for each pig was performed as follows: (a) CbFAS was performed for a post-EMR mucosal defect for Pig A; (b) CbFAS for post-EMR scar for Pig B, and (c) EMR for post-CbFAS scar for Pig C. All pigs were euthanized at 32 days after the initial procedure, and the tissue damage was evaluated.Results: All endoscopic procedures were followed as scheduled. None of the subjects experienced anorexia, rapid weight loss, bleeding, and perforation during the observation period. They were euthanized at 32 days after the initial endoscopic procedure. On histological assessment, there was little difference between the tissue that was treated with CbFAS alone and that treated with CbFAS in combination with ER.Conclusion: Combination therapy with ER and CbFAS can be technically feasible, and its outcome was not significantly different from CbFAS alone in terms of tissue damage.

Download Full-text

Tissue Damage in the Canine Normal Esophagus by Photoactivation with Talaporfin Sodium (Laserphyrin): A Preclinical Study

PLoS ONE ◽

10.1371/journal.pone.0038308 ◽

2012 ◽

Vol 7 (6) ◽

pp. e38308 ◽

Cited By ~ 14

Author(s):

Takahiro Horimatsu ◽

Manabu Muto ◽

Yusuke Yoda ◽

Tomonori Yano ◽

Yasumasa Ezoe ◽

...

Keyword(s):

Tissue Damage ◽

Preclinical Study ◽

Talaporfin Sodium ◽

Normal Esophagus

Download Full-text

Antitumor Efficacy of Combination Therapy Consisting of S-1, Leucovorin, and Oxaliplatin against Human Gastric Cancer Xenografts

Chemotherapy ◽

10.1159/000486029 ◽

2018 ◽

Vol 63 (1) ◽

pp. 46-52

Author(s):

Hideki Nagase ◽

Fumio Nakagawa ◽

Junji Uchida

Keyword(s):

Gastric Cancer ◽

Combination Therapy ◽

Tumor Volume ◽

Preclinical Study ◽

Antitumor Efficacy ◽

Human Gastric Cancer ◽

Antitumor Activities ◽

Once Daily ◽

Xenograft Models

Background/Aim: A phase 3 trial of S-1, leucovorin (LV), and oxaliplatin for treating gastric cancer is now underway. However, the antitumor efficacy of the combination has not yet been examined in an in vivo preclinical study. This study examined the antitumor efficacy of combination therapy consisting of S-1, LV, and oxaliplatin against 4 human gastric cancer xenografts: NUGC-4, St-40, SC-2, and SC-4. Methods: The antitumor efficacy was evaluated using human gastric cancer xenograft-bearing nude mice. S-1 and LV were administered orally once daily on days 1-7 at doses of 6.9 and 10 mg/kg, respectively. Oxaliplatin was administered intravenously at a dose of 8.3 mg/kg on day 1. The tumor volume was measured on day 15, and the relative tumor volume (RTV) was calculated. Results: In all 4 xenograft models, S-1 alone and oxaliplatin alone, but not LV alone, had significant antitumor activities (p < 0.001). Combination therapy consisting of S-1 and LV resulted in a significantly smaller RTV than S-1 alone (p < 0.001). Combination therapy consisting of S-1 and oxaliplatin also resulted in a significantly smaller RTV than either S-1 alone (p < 0.001) or oxaliplatin alone (p < 0.001). Furthermore, combination therapy consisting of S-1, LV, and oxaliplatin resulted in the highest antitumor activity in these models (p < 0.001 vs. S-1 + LV; p < 0.001 or p = 0.003 vs. S-1 + oxaliplatin). Conclusion: Combination therapy consisting of S-1, LV, and oxaliplatin administered according to a 1-week-on/1-week-off schedule may be useful for the treatment of patients with gastric cancer.

Download Full-text

Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-009-1160-0 ◽

2009 ◽

Vol 66 (2) ◽

pp. 269-276 ◽

Cited By ~ 14

Author(s):

Kaori Fujimoto-Ouchi ◽

Fumiko Sekiguchi ◽

Kaname Yamamoto ◽

Masatoshi Shirane ◽

Yoriko Yamashita ◽

...

Keyword(s):

Combination Therapy ◽

Disease Progression ◽

Preclinical Study ◽

Prolonged Administration ◽

Trastuzumab Monotherapy

Download Full-text

Staged Endoscopic and Combined Open/Endoscopic Approach in the Management of Inverted Papilloma of the Frontal Sinus

American Journal of Rhinology ◽

10.1177/194589240501900504 ◽

2005 ◽

Vol 19 (5) ◽

pp. 442-445 ◽

Cited By ~ 17

Author(s):

Marc G. Dubin ◽

Robert E. Sonnenburg ◽

Christopher T. Melroy ◽

Charles S. Ebert ◽

Charles S. Coffey ◽

...

Keyword(s):

Endoscopic Resection ◽

Frontal Sinus ◽

Inverted Papilloma ◽

Endoscopic Approach ◽

Endoscopic Management ◽

Frontal Recess ◽

Increased Risk ◽

Open Treatment ◽

Initial Procedure ◽

Additional Procedure

Background The endoscopic management of inverted papilloma has gained increasing popularity over the last 10 years. Although early concerns over an increased risk of recurrence seem to have been allayed, the appropriate management of lesions involving the frontal sinus and frontal recess still has to be determined. Methods We performed a retrospective review of the results of all patients with inverted papilloma from 2000 to 2004. Results A total of 18 patients were treated between October 2000 and January 2004. Six patients had frontal sinus involvement at the time of initial evaluation. One of these patients had isolated frontal sinus involvement. These patients were managed with either initial endoscopic resection with determination for the need for an additional procedure at the time of endoscopic resection (n = 5) or open/endoscopic approach for isolated frontal sinus involvement (n = 1). Of the five patients who had their disease managed endoscopically, three patients were determined at the initial procedure to need an osteoplastic flap and, subsequently, were managed successfully with a combined approach. One other patient was initially successfully managed endoscopically but ultimately required an osteoplastic flap for definitive management. The fifth patient was managed entirely endoscopically with multiple procedures. All patients treated with this protocol remain disease free with an average follow-up of 13.3 months. Conclusion The limitations of endoscopic resection of inverted papilloma of the frontal recess can be managed with staged procedures. Initial endoscopic resection of ethmoid/maxillary disease with subsequent open treatment of the frontal sinus has been successful in our experience.

Download Full-text

Management of a large mucosal defect after duodenal endoscopic resection

World Journal of Gastroenterology ◽

10.3748/wjg.v22.i29.6595 ◽

2016 ◽

Vol 22 (29) ◽

pp. 6595 ◽

Cited By ~ 18

Author(s):

Shintaro Fujihara ◽

Hirohito Mori ◽

Hideki Kobara ◽

Noriko Nishiyama ◽

Tae Matsunaga ◽

...

Keyword(s):

Endoscopic Resection ◽

Mucosal Defect

Download Full-text

Gastrointestinal defect closure using a novel through-the-scope helix tack and suture device compared to endoscopic clips in a survival porcine model (with video)

Endoscopy International Open ◽

10.1055/a-1370-9256 ◽

2021 ◽

Vol 09 (04) ◽

pp. E572-E577

Author(s):

Ariosto Hernandez ◽

Neil B. Marya ◽

Tarek Sawas ◽

Elizabeth Rajan ◽

Naomi M. Gades ◽

...

Keyword(s):

Porcine Model ◽

Preclinical Study ◽

Colonic Perforation ◽

Defect Closure ◽

Technical Success ◽

Endoscopic Suturing ◽

Mucosal Defect ◽

Endoscopic Clips ◽

Suture Device

Abstract Background and aims Endoscopic resections are associated with bleeding and perforation and may be managed with through-the-scope (TTS) clips, over-the-scope clips and endoscopic suturing. The aim of this preclinical study was to compare technical success of closure using a novel TTS tissue helix tack and suture device (X-Tack) to TTS clips in a porcine model. Materials and methods Four subjects underwent 40 mucosal resections, diameter range 25–50 mm, in the stomach (n = 24) and colon (n = 16). Closures were randomized to X-Tack (n = 24) or clip (n = 16). Animals underwent weekly endoscopic follow-up for 4 weeks. Results Technical closure with X-Tack was successful in 24 of 24 (100 %) cases and with clips in 13 of 16 cases (81.3 %) (P = 0.0001). One colonic perforation occurred and was successfully managed using X-Tack. The rate of healing was not statistically different between the groups, and all sites healed at 4 weeks including the perforation and were confirmed by histology. Conclusions Compared to TTS clip, X-Tack is superior for effecting large mucosal defect closure, including durable sealing of full-thickness perforation. There was no difference in rate of healing between devices.

Download Full-text

A Patient-Derived Xenograft Model of Parameningeal Embryonal Rhabdomyosarcoma for Preclinical Studies

Sarcoma ◽

10.1155/2015/826124 ◽

2015 ◽

Vol 2015 ◽

pp. 1-7 ◽

Cited By ~ 6

Author(s):

Jody E. Hooper ◽

Emma L. Cantor ◽

Macgregor S. Ehlen ◽

Avirup Banerjee ◽

Suman Malempati ◽

...

Keyword(s):

Kinase Inhibitor ◽

Single Agent ◽

Xenograft Model ◽

Soft Tissue Sarcomas ◽

Preclinical Study ◽

Embryonal Rhabdomyosarcoma ◽

Rapid Weight Loss ◽

Primary Tumor Site ◽

Immunodeficient Mice ◽

Patient Derived Xenograft

Embryonal rhabdomyosarcoma (eRMS) is one of the most common soft tissue sarcomas in children and adolescents. Parameningeal eRMS is a variant that is often more difficult to treat than eRMS occurring at other sites. A 14-year-old female with persistent headaches and rapid weight loss was diagnosed with parameningeal eRMS. She progressed and died despite chemotherapy with vincristine, actinomycin-D, and cyclophosphamide plus 50.4 Gy radiation therapy to the primary tumor site. Tumor specimens were acquired by rapid autopsy and tumor tissue was transplanted into immunodeficient mice to create a patient-derived xenograft (PDX) animal model. As autopsy specimens had an ALK R1181C mutation, PDX tumor bearing animals were treated with the pan-kinase inhibitor lestaurtinib but demonstrated no decrease in tumor growth, suggesting that single agent kinase inhibitor therapy may be insufficient in similar cases. This unique parameningeal eRMS PDX model is publicly available for preclinical study.

Download Full-text

Effectiveness of topical budesonide in preventing esophageal strictures after endoscopic resection of esophageal cancer

Endoscopy International Open ◽

10.1055/a-1266-3423 ◽

2020 ◽

Vol 08 (12) ◽

pp. E1795-E1803

Author(s):

Steffi Elisabeth Maria van de Ven ◽

Manon J.B.L. Snijders ◽

Marco J. Bruno ◽

Arjun Dave Koch

Keyword(s):

Esophageal Cancer ◽

Endoscopic Resection ◽

Esophageal Stricture ◽

Oral Treatment ◽

Preventive Treatment ◽

Control Groups ◽

Early Esophageal Cancer ◽

Mucosal Defect ◽

Stricture Rate ◽

Esophageal Strictures

Abstract Background and study aims A disadvantage of endoscopic resection (ER) of early esophageal cancer (EC) is the high stricture rate after resection. A risk factor for stricture development is a mucosal defect after ER of ≥ 75 % of the esophageal circumference. Stricture rates up to 94 % have been reported in these patients. The aim of this study was to investigate the effectiveness of oral treatment with topical budesonide for stricture prevention after ER of early EC. Patients and methods We performed a retrospective analysis of a prospective cohort study of patients who received topical budesonide after ER of EC between March 2015 and April 2020. The primary endpoint was the esophageal stricture rate after ER. Stricture rates of our cohort were compared with stricture rates of control groups in the literature. Results In total, 42 patients were treated with ER and topical budesonide. A total of 18 of 42 patients (44.9 %) developed a stricture. The pooled stricture rate of control groups in the literature was 75.3 % (95 % CI 68.8 %-81.9 %). Control groups consisted of patients with esophageal squamous cell carcinoma with a mucosal defect after ER of ≥ 75 % of the esophageal circumference. Comparable patients of our cohort had a lower stricture rate (47.8 % vs. 75.3 %, P = 0.007). Conclusions Topical budesonide therapy after ER for EC seems to be a safe and effective method in preventing strictures. The stricture rate after budesonide treatment is lower compared to the stricture rate of patients who did not receive a preventive treatment after ER reported in the literature.

Download Full-text